No trial has compared them directly on a meaningful endpoint. NR has more randomised data; NMN has the highest-profile single result.

Why does NAD+ have the least data?

It is the hardest to deliver into cells, so researchers work with precursors instead.

Are they competing compounds?

No — they are successive stages of one conversion pathway. Choosing between them is choosing where to enter it.

NAD+

NAD+, NMN and NR: Three Points on One Pathway

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-234 cited sources

These are not alternatives to each other but successive stages of one pathway: NR converts to NMN, NMN converts to NAD+. Working backwards down the pathway gives smaller, more deliverable molecules — which is why the trial evidence sits with the precursors.

Key facts

NR: 255.25 Da — two steps back
NMN: 334.22 Da — one step back
NAD+: 663.4 Da — the endpoint
Most trial data: NR
Highest-profile single result: NMN (Science 2021)
Hardest to deliver: NAD+

One pathway, three points

The framing as three competing products obscures the chemistry. Cells phosphorylate NR to make NMN, then adenylylate NMN to make NAD+. Choosing between them is choosing where to enter a sequence, not choosing between different mechanisms.

Why earlier is easier

Each step forward adds mass and charge. NR has no phosphate; NMN has one; NAD+ has two in a pyrophosphate bridge. Since charge is what blocks membrane crossing, the compound furthest back is the one most readily delivered — and the finished coenzyme is the one that cannot make the final step from outside a cell.

Research material referenced

NAD+ 500mg — third-party HPLC tested

View — £49.99

Where the evidence sits

NR has the larger randomised trial footprint, including NADPARK in Cell Metabolism and Orr's placebo-controlled study in GeroScience. NMN has the single highest-profile result in Yoshino's 2021 Science paper on muscle insulin sensitivity, plus Yi's 2023 efficacy and safety work. NAD+ itself has essentially no comparable randomised human literature.

The argument each side makes

NMN advocates note it is one step closer to the endpoint. NR advocates note it is smaller, uncharged at the relevant position, and has more trial data. Both arguments are reasonable and neither is decisive, because no trial has directly compared them on a meaningful endpoint.

What this means for a product labelled NAD+

It is the least-studied of the three in humans and the hardest to deliver into cells. That is worth stating plainly, and it is the opposite of what the naming suggests — the finished molecule sounds like the most direct option and is in fact the least.

Quick reference

	MW	Charge	Randomised human data
NR	255.25 Da	Lowest	Most
NMN	334.22 Da	Intermediate	Some, incl. Science 2021
NAD+	663.4 Da	Two phosphates	Essentially none

Extended research context

The NAD+ deep dive

Deep dive: the compound in this catalogue that is not a peptide

NAD+ contains no amino acids and no peptide bonds. It is a dinucleotide - a nicotinamide nucleotide and an adenine nucleotide joined through a pyrophosphate bridge - which is the structural grammar of ATP and of RNA, not of a protein. It sits in a peptide catalogue because it reaches the same buyers, not because it belongs there. Saying so matters practically rather than pedantically: essentially all of the general handling guidance on this site is written for peptides and is the wrong guidance here. There is no sequence to verify, so purity by amino acid analysis is meaningless. There are no deletion sequences, because there is no stepwise coupling to produce them. Net peptide content, the figure that decides how much material a lyophilised peptide vial actually contains, has no analogue at all. Even the instruction that does carry over - dry, cold, dark - protects different chemistry, guarding glycosidic and pyrophosphate bonds rather than peptide bonds and methionine residues.

Deep dive: why the finished molecule is the least deliverable of the three

NAD+ carries two negatively charged phosphates and weighs 663.4 Da, and neither property is compatible with crossing a lipid bilayer. Extracellular NAD+ is also actively consumed: CD38 is an ectoenzyme with its active site facing outward, and Covarrubias and colleagues reported in Nature Metabolism in 2020 that senescent cells drive tissue NAD+ decline specifically by raising CD38 activity. Put those together and administered NAD+ is a molecule that cannot get in and is being degraded while it waits. Whatever follows most plausibly runs through its breakdown to smaller nicotinamide-containing species, which cells then take up and rebuild NAD+ from internally - which is to say, through exactly the precursors people otherwise take directly. This is why every substantial randomised trial in the field used nicotinamide riboside at 255.25 Da or nicotinamide mononucleotide at 334.22 Da rather than the coenzyme itself. The naming inverts the pharmacology: the finished molecule sounds like the most direct option and is the least.

Deep dive: good early evidence, and the gap that keeps getting closed rhetorically

The randomised human literature here is better than for most of this catalogue. NADPARK was a randomised phase I trial of nicotinamide riboside in Parkinson disease in Cell Metabolism. Orr and colleagues ran a randomised placebo-controlled study in older adults in GeroScience. Yoshino and colleagues published NMN and muscle insulin sensitivity in Science. These are real trials in real journals. What they measured, largely, is whether the intervention does what it is supposed to biologically - and raising a biomarker is not the same as changing an outcome. The step that gets taken rhetorically is from a decline that is real, through a mechanism that is identified, to a benefit that has not been demonstrated. Each link looks small; the chain is not. Nothing in this field approaches the scale of what settled the incretin questions, where TRIUMPH alone enrolled more than 5,800 participants with hard clinical endpoints.

Research applications

▸Cellular NAD+ metabolism and salvage pathway research
▸Sirtuin, PARP and CD38 enzyme activity studies
▸Redox biochemistry and NAD+/NADH ratio measurement
▸Cellular senescence and ageing biology research
▸Mitochondrial function and metabolic assay work
▸Comparative precursor uptake and conversion studies

Handling checklist

✓Verify against CID 5892, 663.4 Da, C21H27N7O14P2 - not by sequence
✓Do not apply peptide purity or net peptide content logic - neither exists here
✓Store lyophilised, cold, dry and protected from light
✓Prepare solutions fresh; nucleotide bonds hydrolyse readily in water
✓Be aware NAD+ and NADH are separately quantifiable oxidation states
✓Identity is confirmed by mass and chromatography against a reference standard

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Applying peptide handling and purity guidance to NAD+

Fix: It is a dinucleotide with no peptide bonds. Sequence verification, protease concerns, disulfide chemistry and net peptide content are all inapplicable.

✗ Assuming administered NAD+ enters cells intact

Fix: Two negative phosphate charges and 663 Da prevent membrane crossing, and CD38 degrades it extracellularly. Effects most plausibly run through breakdown products.

✗ Reading precursor trial results as evidence for NAD+ itself

Fix: Every substantial randomised trial used NR or NMN. NAD+ has essentially no comparable human literature.

✗ Treating a biomarker increase as a demonstrated benefit

Fix: Raising NAD+-related markers is reasonably supported. Durable clinical outcome data does not exist.

✗ Taking a precursor's food supplement status as evidence of efficacy

Fix: Supplement frameworks assess safety for consumption, not efficacy, and permit no therapeutic claims.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Which is best?: No trial has compared them directly on a meaningful endpoint. NR has more randomised data; NMN has the highest-profile single result.
Why does NAD+ have the least data?: It is the hardest to deliver into cells, so researchers work with precursors instead.
Are they competing compounds?: No — they are successive stages of one conversion pathway. Choosing between them is choosing where to enter it.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More NAD+ articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum